4.0 Article

Normocalcemic Primary Hyperparathyroidism

期刊

JOURNAL OF CLINICAL DENSITOMETRY
卷 16, 期 1, 页码 33-39

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jocd.2012.12.001

关键词

Normocalcemic primary hyperparathyroidism; parathyroid hormone; PTH(1-84)

资金

  1. National Institutes of Health [DK32333, DK074457, DK095944]
  2. NPS Pharmaceuticals
  3. Amgen

向作者/读者索取更多资源

Primary hyperparathyroidism, a common endocrine disorder, is traditionally defined by hypercalcemia and elevated levels of parathyroid hormone (PTH). A newer presentation of primary hyperparathyroidism has been described over the past decade, in which PTH is elevated but serum calcium is consistently normal, in the absence of secondary causes of hyperparathyroidism, such as renal disease or vitamin D deficiency. Recognition of this phenotype of primary hyperparathyroidism, normocalcemic primary hyperparathyroidism, supports a biphasic chronological time course in some individuals in which PTH levels are first elevated but serum calcium is normal, followed by the development of frank hypercalcemia. This review focuses on the available literature regarding this newly described phenotype of primary hyperparathyroidism.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据